Novo Nordisk Stock Gains Momentum: Why Oral Wegovy Launch Could Reshape Its Future

The past couple of years have been challenging for Novo Nordisk investors, as the Danish pharmaceutical giant watched its weight-loss medicine market share slip to competitor Eli Lilly. But recent developments suggest a turning point may be near. Novo Nordisk’s latest move—launching an oral formulation of Wegovy—could prove transformative for both the company’s competitive position and investor interest in its stock.

The Impressive Debut of Oral Wegovy

After receiving regulatory approval in December, Novo Nordisk introduced its oral version of Wegovy to the market earlier this month, and initial market response has been remarkably strong. According to industry estimates, the prescription volume for oral Wegovy in its first two weeks matched or exceeded early-stage adoption rates for both the injectable Wegovy and Eli Lilly’s current market-leading Zepbound. While maintaining this momentum remains uncertain, these opening numbers suggest the company has successfully tapped genuine demand for an alternative delivery method.

Expanding the Market Beyond Injections

The strategic brilliance of offering an oral alternative lies not simply in replacing existing sales, but in reaching an entirely new patient population. Many potential users avoid injectable treatments due to needle anxiety or the strict cold-storage requirements that make the subcutaneous Wegovy cumbersome. The oral formulation removes these barriers while offering another compelling advantage: lower out-of-pocket costs for uninsured patients. This multi-pronged appeal positions oral Wegovy to expand Novo Nordisk’s addressable market rather than merely redistributing existing revenue. Analyst projections suggest the oral formulation could achieve peak annual sales around $3.3 billion—a meaningful contributor to growth.

Pipeline Strength and Competitive Positioning

Even as Eli Lilly prepares to launch its own GLP-1 oral therapy later this year, Novo Nordisk’s broader development strategy provides confidence. The company has submitted CagriSema for regulatory approval—a candidate that demonstrated superior efficacy to Wegovy in phase 3 testing. Additionally, it’s advancing Amycretin, a next-generation weight-loss medicine, through late-stage trials. Beyond these near-term catalysts, Novo Nordisk maintains a deep pipeline of early-stage candidates. Despite intensifying competition from Eli Lilly and emerging players seeking market entry, this portfolio depth suggests the company can sustain robust revenue and earnings growth over the medium term.

Investment Perspective: Should You Consider NVO?

Novo Nordisk shares remain significantly depressed from their recent highs, reflecting the market’s concerns about competitive pressures and market share loss. Yet at current valuations, the combination of oral Wegovy’s promising launch, a strong upcoming pipeline, and reasonable recovery potential warrants serious consideration from growth-oriented investors. The company’s plan is not merely to hold its own, but to reclaim leadership through innovation. While no investment is without risk, Novo Nordisk stock on the dip presents an interesting opportunity to gain exposure to the high-growth weight-loss medicine sector through a diversified pipeline approach.